USFDA plant clearances delayed
Bengaluru and Malaysia facilities have pending USFDA inspections; delays could impact Aspart, Bevacizumab, and other biosimilar launches in the US.
high · analyst_questionBiocon Limited — Q2 FY25
Biocon's Q2 FY25 consolidated revenue from operations grew 8% YoY to ₹3,590 crore, driven by biosimilars (up 19% like-for-like) but offset by generics decline (-8%) and flat Syn...
neutral
medium
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Generics pricing pressure persists
Continued pricing pressure in the US generics market has impacted margins; recovery depends on cost improvements and new launches.
medium · management_commentaryHumira biosimilar market share growth slow
Despite market share gains, Humira biosimilar adoption has been slower than expected; pricing competition may limit upside.
medium · analyst_questionHigh net debt and capex outflows
Consolidated net debt increased to $1.4 billion despite refinancing; high capex (~₹900 crore in H1) may pressure free cash flow.
medium · data_observation